MicroPulse ® Transscleral Laser Therapy (TLT), continuous-wave transscleral cyclophotocoagulation (CW-TSCPC), and MicroPulse Laser Trabeculoplasty (MLT) are non-incisional treatments that expand ways to manage, preserve, and prolong vision for glaucoma patients.
Sweep Management Software for MicroPulse TLT is now integrated into the Cyclo G6 ® Glaucoma Laser System, and supports the sweep duration methodology shared by the International MicroPulse TLT Delphi Panel.
Glaucoma, comprehensive plus retina surgeons will present best practices using Iridex MicroPulse, Endpoint Management ® and continuous-wave laser technologies at our booth #5139.
MOUNTAIN VIEW, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) — Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, will showcase non-incisional glaucoma treatments, introduce its Sweep Management Software program, and host 8 physician presentations in the 2022 American Academy of Ophthalmology (AAO) annual meeting in Chicago, September 30 – October 3.
MicroPulse Transscleral Laser Therapy (TLT) & Attract Management Software
MicroPulse TLT is a versatile, non-incisional plus repeatable procedure for the treatment of glaucoma performed with the Iridex Cyclo G6 ® Laser beam System and MicroPulse P3 ® Delivery Device. The Cyclo G6 now provides Mop Software, which empowers cosmetic surgeons to customize each MicroPulse TLT treatment to achieve optimal results with regard to a wide range of glaucoma patients. Surgeons set the particular power, the sweep duration, and the particular number of sweeps in a specific treatment desired for each patient. Additionally , new audible tones help the physician meter their attract speed to aid accurate dosing and clinical results. Syril Dorairaj, MD, Professor associated with Ophthalmology, Jacksonville, FL comments, “The Mop Management Software program aids our own ability to deliver the desired dosing, and improves our confidence in this valuable treatment tool. ”
MicroPulse TLT can reduce intraocular pressure (IOP) as much as 25% to 45% for a broad variety of glaucoma types and severities, as reported in peer-reviewed literature. It can be used as the stand-alone therapy or in combination with cataract/MIGS cases or prior to incisional procedures. MicroPulse TLT reimbursement is covered by CPT code 66710.
“MicroPulse TLT is a powerful device that may help us to preserve our patients‘ vision as they progress through their glaucoma journey, ” says Brian Jerkins, MD, Hamilton Eye Institute, University of Tennessee Health Science Center in Memphis, TN.
Continuous-wave Transscleral Cyclophotocoagulation (CW-TSCPC)
CW-TSCPC, is performed with the particular Cyclo G6 using the G-Probe ® and G-Probe Illuminate ® delivery devices. CW-TSCPC offers a cost-effective combination of safety, efficacy, plus ease of use within a non-incisional approach to glaucoma care. Extensive medical literature facilitates CW-TSCPC because a highly effective and durable treatment typically used for later-stage glaucoma when an immediate plus major IOP reduction is needed.
“Recovery with continuous wave TSCPC is much more rapid and the postoperative treatment much less involved than along with someone who has had an incisional glaucoma case in a surgical center, ” said Mahmoud A. Khaimi, MD, Clinical Professor, James P. Luton, MD Endowed Chair in Ophthalmology; Glaucoma Fellowship Director, Dean McGee Eye Institute.
MicroPulse Laserlight Trabeculoplasty (MLT)
Iridex provides several laser platforms that support MLT, an easy to perform, safe and effective therapy option earlier to, or as a good adjunct in order to, topical medication. MLT addresses concerns associated with patient compliance with clinical therapy, reduces patient costs, and avoids side effects associated with medications.
“MLT will be both safe and durable. This therapy can be considered the first-line treatment for glaucoma patients, as well since patients who haven’t seen significant effects from medicines, ” stated Ike Ahmed, MD, FRCSC, Professor, John Moran Vision Center, University of Utah.
Iridex’ laser beam systems regarding MLT are usually ideal intended for a multispecialty practice as they also can be used to treat retinal disorders in MicroPulse and continuous-wave therapy modes.
“We are excited to display our non-incisional laser treatment technologies that will offer doctors safe plus effective options to handle their patients’ glaucoma and retinal care, ” said David I. Bruce, President and CEO of Iridex. “Our Spread around Management Software is the particular latest upgrade to our Cyclo G6 laserlight which guides physicians through the MicroPulse TLT therapy procedure. In addition , our Iridex Academy focuses on advanced peer-to-peer training to help surgeons optimize their MicroPulse TLT patient outcomes. ”
Expert surgeons will be at the booth #5139 to share their experience and treatment pearls making use of Iridex’ systems for the therapy of glaucoma and retinal disorders. Click to view the schedule.
For more information, please contact your Iridex sales professional or Iridex customer service from 1 . 800. 388. 4747 or [email protected] com . Additional resources are available at www.iridexglaucoma.com
Iridex is a worldwide leader inside developing innovative and versatile laser-based medical systems, shipping devices, plus consumable instrumentation for that ophthalmology market. The Company’s proprietary MicroPulse ® technology delivers a differentiated treatment that provides secure, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’ products treat glaucoma, diabetic macular edema, plus other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. With regard to more info, visit www.iridex.com .
Iridex Media Contact
802. 598. 3408
ashley. [email protected] com